Researcher in lab

Find clinical trials

Our clinical trial portfolio is one of the largest in the country. We have more than 700 clinical trials open across 30 clinical units.

Find Melbourne Sexual Health Centre research studies and clinical trials
Clear filter
637 clinical trials found
Clinical trials

POLARIS-3

A Single-Arm Registrational Phase III Study of Olverembatinib in the Treatment of Patients with SDH-Deficient Gastrointestinal Stromal Tumor [POLARIS-3] (NCT06640361)

Currently recruiting

POLARIS1

A Global Multicenter, Open Label, Randomized Phase 3 Registrational Study of Olverembatinib Combined with Chemotherapy Versus Imatinib Combined with Chemotherapy in Patients with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL). (NCT06051409)

Currently recruiting

PORTHOS Study

A Prospective angiOtensin vs. noRadrenaline Trial for Hypotension management to reduce length Of hospital stay in Cardiac Surgery (the PORTHOS study) (ACTRN12623000848606p)

Currently recruiting

Portico IDE

Portico Re-sheathable Transcatheter Aortic Valve System US IDE Trial (PORTICO)

The PORTICO pivotal IDE trial is a prospective, multi-center, randomized, controlled clinical investigation study designed to evaluate the safety and effectiveness of the SJM Portico Transcatheter Heart Valve and Delivery Systems (Portico) via transfemoral and alternative delivery methods in high-risk and extreme-risk patients.

No longer recruiting

Portico NG

Portico NG - Evaluation of the Navitor Transcatheter Aortic Valve in High and Extreme Risk Patients with Symptomatic Severe Aortic Stenosis

The primary objective of this clinical study is to evaluate the acute safety and effectiveness of the Navitor Transcatheter Aortic Heart Valve as assessed by the rate of all-cause mortality at 30 days and the rate of moderate or greater paravalvular leak at 30 days. The results from this study will be descriptively compared to the data from the first-generation Portico Transcatheter Aortic Heart Valve and commercially available TAVI devices studied in the same patient population (e.g. high and extreme surgical risk).

No longer recruiting

POST-ETERNAL

Extending the time window for Tenecteplase by Effective RecanalizatioN of bAsilar artery occLusion in patients with POSTerior circulation stroke (NCT05105633)

Currently recruiting

POTAT

A Pilot Study of Post Operative Iron Infusion for the Treatment of Anaemia in trauma Patients (ACTRN12624000410550)

No longer recruiting

PRAX-628-212

An Open Label Clinical Trial to Evaluate the Efficacy and Safety of PRAX-628 in Adult Patients with Focal Onset or Primary Generalized Tonic-Clonic Seizures (NCT06908356)

The main purpose of this study is to see how well PRAX-628 works in treating focal onset seizures (the type of seizure that starts when only one area of the brain starts firing uncontrolled electrical signals) and primary generalised tonic-clonic seizures (the type of seizure that occurs when uncontrolled electrical activity affects the entire brain from the start). Additional purposes of this study are to see how safe PRAX-628 is and how the body processes (pharmacokinetics, PK) it. In this study, all participants will receive PRAX-628 30 mg (3 x 10 mg capsules) once daily (QD) for 8 weeks.
Currently recruiting

PREDICT

PREdiction and Diagnosis using Imaging and Clinical biomarkers Trial in Traumatic Brain Injury (ACTRN12620001360909)

No longer recruiting

PrEEN

Prospective assessment of the effects of Exclusive Enteral Nutrition on inflammation, epithelial integrity and body composition in patients with Crohn’s disease (ACTRN12625000357459)

Currently recruiting

PREVAIL

Obicetrapib and Cardiovascular Outcomes: A Placebo-Controlled, Double-Blind, Randomized Phase 3 Study to Evaluate the Effect of 10 mg Obicetrapib in Participants With Atherosclerotic Cardiovascular Disease (ASCVD) Who are Not Adequately Controlled Despite Maximally Tolerated Lipid-Modifying Therapies (NCT05142722)

No longer recruiting

PREVENT-NEURO

Prophylaxis against early ventilator-associated infections to reduce mortality in mechanically ventilated ICU patients with acute brain injuries (NCT06819592)

The PREVENT-NEURO study will test the hypothesis that among adults with acute brain injuries receiving invasive mechanical ventilation in the ICU (participants), one dose of 2g of intravenous ceftriaxone administered as soon as practical after endotracheal intubation (intervention), compared to a matched placebo (comparator), reduces 90-day mortality (primary outcome).
Coming soon

PREVISION

A Prospective, Multicenter, Single Arm, Non-Randomized, Study of BD™ Sirolimus Drug Coated Balloon Catheter for Treatment of Femoropopliteal Arteries (NCT05556681)

Currently recruiting

PRIME-OOHCA

PRotecting cerebral injury and IMproving outcomEs with SGLT2 inhibitors in comatose Out-Of-Hospital Cardiac Arrest survivors – a Pilot Study (ACTRN12624001183572)

A double blinded randomised controlled pilot study comparing the outcomes of dapagliflozin vs placebo in patients with comatose cardiac arrest, with respect to hypoxic brain and ischaemia reperfusion injury
Currently recruiting

PRO-DVd

Patient Reported Outcomes in patients received DVd for relapsed MM (ACTRN12618000659202)

No longer recruiting

PROBE

A First-in-Human Phase I trial of ATG-101 in Patients with Metastatic/Advanced Solid Tumors and Mature B-cell Non-Hodgkin Lymphomas (NCT04986865)

Currently recruiting

PROBE-DFU Trial

Pilot randomised controlled trial of probe to bone diabetic foot ulcer therapy (ACTRN12624000266561)

Probe-to-bone (PTB) test is a bedside test used to assess for bone infection in patients with diabetic foot ulcers, where a blunt metal probe is used to test for presence of bone within the ulcer bed. This study aims to evaluate the safety and feasibility of treating patients with diabetic foot ulcers and positive PTB test with shorter courses of antibiotic therapy in a low-risk setting.
Currently recruiting

PROCORA

PROvocative CORonary testing in unexplained cardiac Arrest (ACTRN12624001248550)

Currently recruiting

Progress-AD

A Phase 2, Parallel Group, Randomized, Double-Blind, Placebo-Controlled, 3-Arm, Multicenter Treatment Study to Evaluate the Efficacy and Safety of GSK4527226 [AL101] Intravenous Infusion Compared with Placebo in Patients with Early Alzheimer’s Disease (NCT06079190)

Currently recruiting

PROMPT O2

Perioperative Medicine Platform Trial (NCT07186634)

Giving a lot of oxygen may decrease the risk of infections after surgery. On the other hand, it is also possible that giving a conservative amount of oxygen (instead of a large amount) might protect organ functions and improve other aspects of recovery after surgery. We are comparing three (3) different ways of giving oxygen. You have an equal chance of receiving one of the following three treatments during and after surgery: Liberal oxygen - at least 80% oxygen; Conservative oxygen - the smallest amount of oxygen needed to safely achieve normal oxygen levels in the blood (but more than the oxygen in room air); Standard oxygen - oxygen in a middle range between the liberal and conservative treatments.
Currently recruiting
22 23 24 25 26